Literature DB >> 26537685

Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Masaaki Nakashima1, Hirotaka Ode2, Takashi Kawamura3, Shingo Kitamura1, Yuriko Naganawa2, Hiroaki Awazu1, Shinya Tsuzuki1, Kazuhiro Matsuoka2, Michiko Nemoto2, Atsuko Hachiya2, Wataru Sugiura4, Yoshiyuki Yokomaku2, Nobuhisa Watanabe5, Yasumasa Iwatani6.   

Abstract

UNLABELLED: The HIV-1 Vif protein inactivates the cellular antiviral cytidine deaminase APOBEC3F (A3F) in virus-infected cells by specifically targeting it for proteasomal degradation. Several studies identified Vif sequence motifs involved in A3F interaction, whereas a Vif-binding A3F interface was proposed based on our analysis of highly similar APOBEC3C (A3C). However, the structural mechanism of specific Vif-A3F recognition is still poorly understood. Here we report structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Alanine-scanning analysis of Vif revealed that six residues located within the conserved Vif F1-, F2-, and F3-box motifs are essential for both A3C and A3F degradation, and an additional four residues are uniquely required for A3F degradation. Modeling of the Vif structure on an HIV-1 Vif crystal structure revealed that three discontinuous flexible loops of Vif F1-, F2-, and F3-box motifs sterically cluster to form a flexible A3F interaction interface, which represents hydrophobic and positively charged surfaces. We found that the basic Vif interface patch (R17, E171, and R173) involved in the interactions with A3C and A3F differs. Furthermore, our crystal structure determination and extensive mutational analysis of the A3F C-terminal domain demonstrated that the A3F interface includes a unique acidic stretch (L291, A292, R293, and E324) crucial for Vif interaction, suggesting additional electrostatic complementarity to the Vif interface compared with the A3C interface. Taken together, these findings provide structural insights into the A3F-Vif interaction mechanism, which will provide an important basis for development of novel anti-HIV-1 drugs using cellular cytidine deaminases. IMPORTANCE: HIV-1 Vif targets cellular antiviral APOBEC3F (A3F) enzyme for degradation. However, the details on the structural mechanism for specific A3F recognition remain unclear. This study reports structural features of interaction interfaces for both HIV-1 Vif and A3F molecules. Three discontinuous sequence motifs of Vif, F1, F2, and F3 boxes, assemble to form an A3F interaction interface. In addition, we determined a crystal structure of the wild-type A3F C-terminal domain responsible for the Vif interaction. These results demonstrated that both electrostatic and hydrophobic interactions are the key force driving Vif-A3F binding and that the Vif-A3F interfaces are larger than the Vif-A3C interfaces. These findings will allow us to determine the configurations of the Vif-A3F complex and to construct a structural model of the complex, which will provide an important basis for inhibitor development.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26537685      PMCID: PMC4702671          DOI: 10.1128/JVI.02369-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Roderick W Davis; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.

Authors:  Shingo Kitamura; Hirotaka Ode; Masaaki Nakashima; Mayumi Imahashi; Yuriko Naganawa; Teppei Kurosawa; Yoshiyuki Yokomaku; Takashi Yamane; Nobuhisa Watanabe; Atsuo Suzuki; Wataru Sugiura; Yasumasa Iwatani
Journal:  Nat Struct Mol Biol       Date:  2012-09-23       Impact factor: 15.369

5.  APOBEC3F determinants of HIV-1 Vif sensitivity.

Authors:  Allison M Land; Nadine M Shaban; Leah Evans; Judd F Hultquist; John S Albin; Reuben S Harris
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

6.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.

Authors:  Markus-Frederik Bohn; Shivender M D Shandilya; John S Albin; Takahide Kouno; Brett D Anderson; Rebecca M McDougle; Michael A Carpenter; Anurag Rathore; Leah Evans; Ahkillah N Davis; Jingying Zhang; Yongjian Lu; Mohan Somasundaran; Hiroshi Matsuo; Reuben S Harris; Celia A Schiffer
Journal:  Structure       Date:  2013-05-16       Impact factor: 5.006

8.  HIV-1 Vif adaptation to human APOBEC3H haplotypes.

Authors:  Marcel Ooms; Bonnie Brayton; Michael Letko; Susan M Maio; Christopher D Pilcher; Frederick M Hecht; Jason D Barbour; Viviana Simon
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

9.  Great ape genetic diversity and population history.

Authors:  Javier Prado-Martinez; Peter H Sudmant; Jeffrey M Kidd; Heng Li; Joanna L Kelley; Belen Lorente-Galdos; Krishna R Veeramah; August E Woerner; Timothy D O'Connor; Gabriel Santpere; Alexander Cagan; Christoph Theunert; Ferran Casals; Hafid Laayouni; Kasper Munch; Asger Hobolth; Anders E Halager; Maika Malig; Jessica Hernandez-Rodriguez; Irene Hernando-Herraez; Kay Prüfer; Marc Pybus; Laurel Johnstone; Michael Lachmann; Can Alkan; Dorina Twigg; Natalia Petit; Carl Baker; Fereydoun Hormozdiari; Marcos Fernandez-Callejo; Marc Dabad; Michael L Wilson; Laurie Stevison; Cristina Camprubí; Tiago Carvalho; Aurora Ruiz-Herrera; Laura Vives; Marta Mele; Teresa Abello; Ivanela Kondova; Ronald E Bontrop; Anne Pusey; Felix Lankester; John A Kiyang; Richard A Bergl; Elizabeth Lonsdorf; Simon Myers; Mario Ventura; Pascal Gagneux; David Comas; Hans Siegismund; Julie Blanc; Lidia Agueda-Calpena; Marta Gut; Lucinda Fulton; Sarah A Tishkoff; James C Mullikin; Richard K Wilson; Ivo G Gut; Mary Katherine Gonder; Oliver A Ryder; Beatrice H Hahn; Arcadi Navarro; Joshua M Akey; Jaume Bertranpetit; David Reich; Thomas Mailund; Mikkel H Schierup; Christina Hvilsom; Aida M Andrés; Jeffrey D Wall; Carlos D Bustamante; Michael F Hammer; Evan E Eichler; Tomas Marques-Bonet
Journal:  Nature       Date:  2013-07-03       Impact factor: 49.962

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more
  36 in total

1.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity.

Authors:  In-Ja L Byeon; Chang-Hyeock Byeon; Tiyun Wu; Mithun Mitra; Dustin Singer; Judith G Levin; Angela M Gronenborn
Journal:  Biochemistry       Date:  2016-05-19       Impact factor: 3.162

3.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

Review 4.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

5.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

6.  Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.

Authors:  Anjuman Ara; Robin P Love; Tyson B Follack; Khawaja A Ahmed; Madison B Adolph; Linda Chelico
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 7.  Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.

Authors:  Farshad C Azimi; Jeffrey E Lee
Journal:  Protein Sci       Date:  2019-11-29       Impact factor: 6.725

8.  The Structural Interface between HIV-1 Vif and Human APOBEC3H.

Authors:  Marcel Ooms; Michael Letko; Viviana Simon
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

9.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

Review 10.  APOBEC Enzymes as Targets for Virus and Cancer Therapy.

Authors:  Margaret E Olson; Reuben S Harris; Daniel A Harki
Journal:  Cell Chem Biol       Date:  2017-11-16       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.